Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

System being used in John Warin isolation ward at Oxford's John Radcliffe Hospital

A wearable patch (to measure respiratory rate) and wrist-worn pulse oximeter (to measure pulse rate and oxygen saturation), are linked by Bluetooth to a tablet computer

In a Biomedical Research Centre project led by Professor Peter Watkinson (Nuffield Department of Clinical Neurosciences) and Professor Lionel Tarassenko (Institute of Biomedical Engineering, Department of Engineering Science), biomedical engineers and medical researchers have been developing and testing the concept of a virtual High-Dependency Unit (vHDU) for the past 18 months.

A vHDU is a general ward in a hospital in which high-risk patients are monitored using a new generation of wearable sensors measuring pulse rate, respiratory rate and blood oxygen saturation, combined with Bluetooth-linked tablet computers and smart alerting algorithms. The twin aims are to reduce the burden on nursing staff, allowing them to perform vital-sign observations for high-risk patients at the same rate as for lower-risk patients (typically four-hourly), and to improve early detection of abnormal physiological parameters.

Read the full story on the Nuffield Department of Clinical Neurosciences website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.